Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-09-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/9/e002472.full |
| _version_ | 1818987245488570368 |
|---|---|
| author | Hui Zheng Eirini Pectasides Mohamed Uduman Charles S Fuchs James M Cleary Adam J Bass Jérémy Augustin Leonie K de Klerk Anuj K Patel Sarah Derks Nihal Raman Fahire G Akarca Nadine J McCleary Douglas A Rubinson Jeffrey W Clark Bridget Fitzpatrick Lauren K Brais Megan E Cavanaugh Amanda J Rode Melissa G Jean Patrick H Lizotte Matthew J Nazzaro Peter C Enzinger |
| author_facet | Hui Zheng Eirini Pectasides Mohamed Uduman Charles S Fuchs James M Cleary Adam J Bass Jérémy Augustin Leonie K de Klerk Anuj K Patel Sarah Derks Nihal Raman Fahire G Akarca Nadine J McCleary Douglas A Rubinson Jeffrey W Clark Bridget Fitzpatrick Lauren K Brais Megan E Cavanaugh Amanda J Rode Melissa G Jean Patrick H Lizotte Matthew J Nazzaro Peter C Enzinger |
| author_sort | Hui Zheng |
| collection | DOAJ |
| first_indexed | 2024-12-20T19:03:37Z |
| format | Article |
| id | doaj.art-88b5dffda1124385a9d172a7073bce20 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-20T19:03:37Z |
| publishDate | 2021-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-88b5dffda1124385a9d172a7073bce202022-12-21T19:29:20ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-09-019910.1136/jitc-2021-002472Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalHui Zheng0Eirini Pectasides1Mohamed Uduman2Charles S Fuchs3James M Cleary4Adam J Bass5Jérémy Augustin6Leonie K de Klerk7Anuj K Patel8Sarah Derks9Nihal Raman10Fahire G Akarca11Nadine J McCleary12Douglas A Rubinson13Jeffrey W Clark14Bridget Fitzpatrick15Lauren K Brais16Megan E Cavanaugh17Amanda J Rode18Melissa G Jean19Patrick H Lizotte20Matthew J Nazzaro21Peter C Enzinger22Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China8 Department of Medicine, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USAAff2 0000 0004 0486 2652grid.420152.0Agenus Inc. 3 Forbes Road 02421 Lexington MA USA10 Yale Cancer Center, New Haven, Connecticut, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA1 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USAInstitut National de la Santé et de la Recherche Médicale U938, Centre de Recherche de Saint Antoine, Sorbonne Université-Faculté Saint Antoine, Paris, FranceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Amsterdam UMC - Location VUmc, Cancer Center Amsterdam, Amsterdam, The NetherlandsCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USABelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USABelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USABelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USABelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USACenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USAhttps://jitc.bmj.com/content/9/9/e002472.full |
| spellingShingle | Hui Zheng Eirini Pectasides Mohamed Uduman Charles S Fuchs James M Cleary Adam J Bass Jérémy Augustin Leonie K de Klerk Anuj K Patel Sarah Derks Nihal Raman Fahire G Akarca Nadine J McCleary Douglas A Rubinson Jeffrey W Clark Bridget Fitzpatrick Lauren K Brais Megan E Cavanaugh Amanda J Rode Melissa G Jean Patrick H Lizotte Matthew J Nazzaro Peter C Enzinger Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival Journal for ImmunoTherapy of Cancer |
| title | Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival |
| title_full | Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival |
| title_fullStr | Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival |
| title_full_unstemmed | Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival |
| title_short | Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival |
| title_sort | phase ii study of pembrolizumab in refractory esophageal cancer with correlates of response and survival |
| url | https://jitc.bmj.com/content/9/9/e002472.full |
| work_keys_str_mv | AT huizheng phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT eirinipectasides phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT mohameduduman phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT charlessfuchs phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT jamesmcleary phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT adamjbass phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT jeremyaugustin phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT leoniekdeklerk phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT anujkpatel phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT sarahderks phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT nihalraman phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT fahiregakarca phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT nadinejmccleary phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT douglasarubinson phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT jeffreywclark phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT bridgetfitzpatrick phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT laurenkbrais phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT meganecavanaugh phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT amandajrode phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT melissagjean phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT patrickhlizotte phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT matthewjnazzaro phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival AT petercenzinger phaseiistudyofpembrolizumabinrefractoryesophagealcancerwithcorrelatesofresponseandsurvival |